Studies on side effect profile of treated hypertensives on selected pharmacotherapy by Ismail, Marina
STUDIES ON SIDE EFFECT PROFILE OF TREATED 
HYPERTENSIVES ON SELECTED PHARMACOTHERAPY 
by 
DR MARINA ISMAIL 
Dissertation Submitted In Partial Fulfilment Of The 
Requirements For The Degree Of Master Of Medicine 
(Internal Medicine) 
UNIVERSITI SAINS MALAYSIA 
2001 
ACKNOWLEDGEMENTS 
I would like to thank my supervisors. Associate Professor (Dr) Rusli Ismail and 
Professor (Or) Wan Mohamad Wan Bebakar for their valuable advice and 
guidance for the preparation of this dissertation. Their help and guidance has 
made this study possible and has enabled me to be more familiar in designing 
and carrying out research. 
My special gratitude for Ms. Teh Lay Kek from Department of Pharmacy, 
University Malaya for her helped in preparing the questionnaires on quality of life 
assessment. 
Not to forget, my husband En. Zakaria Hamid for his continued support and help 
in preparing the research. Also to my children, Mohd. Amir Ashraf, Mohd. Amir 
Afiq and Nur Ain Shafiqah for their understanding and cooperation during the 
period of this study. 
lastly, I would like to express my heartfelt gratitude to all the volunteers who 
have participated in this study and hope that the results of this study will 
contribute towards improving the management of hypertension. 
11 
This dissertation has got many weaknessess which was highlighted by 
examiners and has been discussed in the viva voce. I have highlighted the 
weaknessess and have written an extra chapter to outline these weaknessess. I 
am also grateful to the examiners for pointing out the weaknessess and gave the 
beneficial comments to prepare this chapter. 
111 
Acknowledgements 
Table of content 
List of Tables 
List of Illustrations 
Abstract 
Bahasa Malaysia 
English 
CHAPTER 
Chapter 1: Introduction 
1. 0 Introduction 
Table of Content 
1.1 Beta blocker as an antihypertensive drug 
1. 2 Health related quality of life 
Chapter 2 : Objectives 
2. Objectives 
Chapter 3 : Method 
3.1 
3.1.1 
3.1.2 
3.2 
3.2.1 
3.2.2 
Patients selection 
Inclusion criteria 
Exclusion criteria 
Study Design and clinical methods 
Laboratory investigations 
Follow-up visits 
iiii 
ii 
iv 
vi 
vii 
viii 
xii 
1 
10 
17 
23 
24 
24 
25 
25 
26 
29 
3.2.3 Criteria for diagnosing hypertension 
3.3 Statistical analysis 
Chapter 4 : Results 
4.1 Demography 
4.2 Hypertension related complications 
4.3 Clinical results 
4.4 Biochemical results 
4.5 Adverse effects 
4. 6 Life satisfactions 
Chapter 5 : Discussion 
Chapter 6 : Conclusion 
Chapter 7 : Critics and limitation 
References 
Appendix 
Appendix I 
Appendix II 
lVI 
29 
29 
31 
39 
41 
47 
51 
62 
65 
79 
80 
87 
95 
96 
Table 1 
Table 4.1.0 
Table 4.1.1 
Table 4.1.2 
Table 4.1.3 
Table 4.2.0 
Table4.3.0 
Table 4.4.0 
Table 4.5.0 
Table 4.6.0 
List of Tables 
General measures of the quality of life. 
Concurrent Antihypertensive drug Received by Patients. 
Racial Distribution Among Study Groups. 
Sexual Distribution Among Study Groups. 
Physical Characteristics of Study Patients. 
Number of Patients Who Reported Stroke/TIA According to 
Treatment Groups. 
Average Blood Pressures and Pulse Rates According to 
Study Groups. 
Results of Laboratory Examination Treatment Groups. 
Ranking of Adverse Events According to Drug Groups. 
Life Satisfaction of the Study Patients. 
VI 
Figure 1. 
Figure 4.1.0 
Figure 4.3.0 
Figure 4.3.1 
Figure 4.3.2 
Figure 4.4.0 
Figure 4.4. 1 
Figure 4.5.0 
Figure 4.5.1 
Figure 4.5.2 
Figure 4.5.3 
List of Illustration. 
Study Design. 
Age Distribution Among Study Patients. 
Systolic Blood Pressure Distribution in Study Patients. 
Diastolic Blood Pressure in Study Patients. 
Percentage of Patients who achieved blood pressure control. 
Serum ALP According to Drug Groups. 
Serum AST According to Drug Groups. 
Adverse Symptoms Reported By All Patients. 
Average Frequency Scores Adverse Symptoms in All 
Patients. 
Severity of Adverse Events Reported. 
Occurrence of Adverse Events According to Drug Groups. 
Vll 
ABSTRACT 
ABSTRAK 
Kajian kesan sampingan terhadap penyakit darah tinggi berdasarkan ubat-
ubatan terpilih. 
Latarbelakang: Penyakit darah tinggi merupakan sejenis penyakit yang 
memberikan implikasi yang besar kepada kesihatan seseorang pesakit. Rawatan 
penyakit ini adalah panting bagi mengurangkan kadar komplikasi dan kematian. 
Kawalan terhadap tekanan darah melalui penggunaan ubat-ubatan yang dapat 
bertindak balas dengan baik, dos yang bersesuian dan kos yang rendah adalah 
diperlukan. Disamping itu, penggunaan ubat yang paling baik dan mempunyai 
kesan sampingan yang paling sedikit perlu diamalkan. lni adalah penting bagi 
mempastikan penggunaan ubat dapat diambil secara berterusan dan kualiti 
kehidupan pesakit dapat dipertingkatkan. Di Hospital USM, metoprolol digunakan 
secara meluas. Metabolismanya dipengaruhi oleh kepelbagaian debrisoquine-
hydroxylase yang mempunyai perbezaan yang ketara antara sesebuah bangsa 
atau etnik. Kebanyakan kesan sampingan mungkin dipengaruhi oleh paras ubat 
yang berlebihan di dalam darah yang diakibatkan oleh kurangnya metabolisms 
dalam tubuh seseorang. Oleh yang demikian, objektif kajian ini adalah untuk 
mengkaji penggunaan metoprolol dan kesan sampingan dalam merawat 
penyakit darah tinggi. Kajian ini juga dibuat bagi menentukan samada pesakit 
yang mendapat kesan sampingan mengalami kualiti kehidupan yang tidak 
memuaskan. Sebagai perbandingan, kajian terhadap pesakit darah tinggi yang 
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mendapat rawatan dengan enalapril atau kombinasi enalapril dan metoprolot 
dilakukan. 
Kaedah: Dua ratus pesakit darah tinggi yang dirawat dengan metoprolol 
dan/atau enalapril di Klinik Pakar Perubatan, HUSM telah dipilih. Pesakit-pesakit 
yang telah disahkan menghidap penyakit kencing man is, penyakit jantung 
koronari, kegagalan buah pinggang yang kronik, kegagalan jantung penyakit-
penyakit kronik yang lain dikecualikan. Pesakit yang mengidap penyakit seperti 
barah telah dikecualikan dari kajian kerana dikhuatiri akan mengganggu 
penyiasatan. Demografi pesakit direkodkan pada lawatan pertama dan 
seterusnya pada lawatan ulangan. Kualiti kehidupan pesakit dikaji berdasarkan 
borang soal selidik. 
Keputusan: Oua ratus pesakit yang dirawat dengan metoprolol dan/atau 
enalapril telah dipilih. Kebanyakan pesakit di dalam kajian ini adalah daripada 
bangsa Melayu. Purata umur pesakit adalah 53.4 tahun dan separuh daripada 
mereka adalah lelaki. 77 pesakit darah tinggi mendapat rawatan 
dengan metoprolol, 99 orang pesakit dirawat dengan enalapril dan 24 orang 
pesakit mendapat rawatan kombinasi metoprolol-enalapril. 48o/o pesakit 
mempunyai purata tekanan darah sistolik 140 mmHg atau kurang dan 28o/o 
mempunyai purata tekanan darah diastolik 80 mmHg atau kurang. 42o/o pesakit 
metoprolol, 43% pesakit enalapril dan 40% pesakit yang mendapat rawatan 
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kombinasi metoprolol-enalapril mempunyai purata tekanan darah sistolik s140 
mmHg dan purata tekanan darah diastolik s 90 mmHg. 
Tidak ada perbezaan statistik yang ketara dalam penyiasatan biokemikal darah 
pesakit dalam kajian ini. Kebanyakan kesan sampingan dilaporkan oleh pesakit 
di dalam kumpulan yang menerima rawatan kombinasi metoprolol-enalapril. 
Walaubagaimanapun. sebahagian kesan sampingan yang dilaporkan lebih 
ketara di dalam pesakit yang dirawat dengan metoprolol. lni meliputi bradikardia ( 
gerakan nadi yang perlahan). sejuk bahagian hujung kaki dan tangan, kencing 
pada waktu malam dan berdebar-debar. Hampir kesemua pesakit melaporkan 
bahawa mereka berpuashati dengan kualiti kehidupan. Sebahagian kecil yang 
tidak berpuashati dengan kualiti kehidupan datangnya dari kumpulan yang 
mendapat rawatan metoprolol. 
Kesimpulan: Kajian ini menunjukkan bahawa tidak sampai separuh daripada 
pesakit kami yang menerima rawatan samada metoprolol, enalapril 
atau kombinasi metoprolol-enalapril mencapai tahap kawalan tekanan darah 
yang memuaskan. Kebanyakannya melaporkan bahawa mereka mendapat 
kesan sampingan daripada rawatan yang diberikan. Kesan sampingan ini berkait 
rapat dengan dos ubat yang diberi terutamanya pesakit yang mendapat rawatan 
metoprolol. lni mungkin menyebabkan kurangnya penggunaan ubat secara 
berterusan menyebabkan tekanan darah tinggi tidak dapat dikawal secara 
berkesan. lni juga mungkin dipengaruhi oleh kurangnya kebolehan untuk 
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metabolisma metoprolol terhadap pesakit yang mempunyai kepelbagaian genetik 
debrisoquine-hydroxylasde. Oleh itu, kajian lanjut berkenaan dengan 
kepelbagaian genetik dan fenotaip akan memberikan jawapan kepada masalah 
di atas. 
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ABSTRACT 
Background: Hypertension is a major public health problem because of its 
consequences. Its treatment is crucial and goals include to decrease ~orbidity 
and mortality associated with hypertension by decreasing blood pressure using 
drugs that have good tolerance, dosing convenience and low cost. As many 
antihypertensives are now available, it is important to choose the most 
appropriate drug in terms of efficacy and with least side effect in order to 
improve compliance and the patient's quality of life. In HUSM, metoprolol is a 
widely used. Its metabolism is mediated by the polymorphic debrisoquine-
hydroxylase that exhibits large inter ethnic difference. As most of its adverse 
reactions could be due to excessive plasma concentrations, its use among our 
local population may therefore be associated with adverse effects due to reduced 
capacity of the local population to metabolise the drug. The objedives of this 
study were therefore to investigate the use of metoprolol in the treatment of 
hypertension in relation to the incidence of adverse drug reactions it caused. We 
would also determine whether patients who experienced adverse reactions 
suffered reduced quality of life. As controls, we used patients who received 
enalapril or enalapril combined with metoprolol in the treatment of their 
hypertension. 
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Method: Two hundred hypertensive patients treated with metoprolol and/or 
enalapril at the Hypertensive Clinic, HUSM were recruited. Those excluded were 
patients diagnosed to have diabetes mellitus, ischaemic heart disease, chronic 
renal failure, congestive cardiac failure and those who suffered from other 
chronic diseases for example malignancy, which may interfere with the proper 
use of the investigation instrument. Patients' demography were recorded and 
biochemical profile were taken. The clinical observation were recorded during the 
first visit and at follow up. Their quality of life assessment were assessed using 
questionnaire. 
Result: Two hundred hypertensive patients treated with metoprolol 
andlon enalapril were enrolled. The majority were Malays. Their age 
averaged 53.4 years and half were males. Seventy-seven received 
metoprolol as their primary antihypertensive drug, 99 were on enalapril 
and 24 were on combination metoprolol-enalapril therapies. 48% had 
systolic blood pressure (SBP) that averaged 140 mmHg or below and 
28o/o had diastolic blood pressure (DBP) that averaged 80 mmHg or 
below. 42% metoprolol patients, 43o/o enalapril patients and 40% 
combined-therapy patients had blood pressure control (average SBP =s;; 
140 mmHg and average DBP s 90 mmHg) p=0.979. 
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No statistical significant difference in blood chemistries occurred among 
the study groups. Adverse events were reported frequently by the 
patients and were most frequently reported by patients on combination-
therapy. Some adverse effects were more significant with patients on 
metoprolol. These included bradycardia, cold extremities, nocturia, and 
palpitation. Almost all however reported that they were satisfied with their 
lives but those who said that they were not satisfied came from the 
metoprolol group. 
Conclusion: Our study showed that less than half of our patients treated with 
either metoprolol, enalapril or metoprolol-enalapril combination achieved 
satisfactory blood pressure controls. Many however reported adverse effects. 
Dose-related side effects appeared to occur commonly in patients given 
metoprolol and this could have lead to reduced compliance and hence 
inadequate blood pressure control. This could be due to reduced ability to 
metabolise metoprolol that could have occurred with some patients due to 
debrisoquine hydroxylase genetic polymorphism. Further work involving 
phenotyping and genotyping for the polymorphism may provide insights into this 
problem. 
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CHAPTER ONE 
INTRODUCTION 
1. INTRODUCTION 
Hypertension is a major public health problem because of its consequences. It 
is an established risk factor for stroke, myocardial infarction, and premature 
cardiovascular death (Hennekens, 1998). As a risk factor for cardiovascular 
disease, hypertension almost competes with elevated plasma cholesterol for 
first place (Kaplan, 1983; Mansour et al, 1997). Thus although the facts about it 
are common knowledge, the consequences of hypertension bear repeating 
(McCarthy, 1997). Hypertension is widespread and is a major risk factor in 
myocardial infarctions. It is also the chief cause of stroke in people under age 
65 and only diabetes is more instrumental than hypertension in causing end-
stage renal failure. 
The treatment of hypertension has been shown to also protect against stroke. 
On a population basis, it has been estimated that a reduction in blood pressure 
of 2 mmHg would result in a 15% reduction in risk of stroke and transient 
ischaemic attack and a 6°A, reduction in risk of coronary heart disease (Kothen 
et al, 1988). Stamler et al (1993) reviewed prospective population studies on 
blood pressure and cardiovascular risks. They concluded that systolic blood 
pressure and diastolic blood pressure had a continuous, graded, strong, 
independent and etiologically significant 
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relationship to a variety of outcome variables, including coronary heart 
disease, stroke, cardiac abnormality and mortality. Data from the Framingham 
Heart study (Kannel et al, 1971) showed that those with borderline isolated 
systolic blood pressure (SBP: 140-159 mmHg, DBP: ~ 90 mmHg) were at high 
risk of developing hypertension or major morbid or fatal events than people with 
normal blood pressure. They found that 80% of men and women with 
borderline hypertension developed definite hypertension after 20 years and 
experienced excessive long-term risk of cardiovascular disease and death. For 
the middle aged and older persons systolic blood pressure relates more 
strongly to risk than diastolic blood pressure (Potter and High, 1990). A pilot 
study of systolic hypertension in the elderly (SHEP) also concluded that the 
prevalence of isolated systolic hypertension (SBP ~160 mmHg and DBP s 90 
mmHg) increased from about 8% among peoples in their sixties to 22o/o by the 
age of 80 (SHEP Cooperative Research Group, 1991). 
As evidence shows that hypertension increases with age, the problem of 
hypertension will increase in importance since the number of individuals over 
eo years is expected to increase steadily in the next few decades to levels 
approaching one fourth of the total population. More individuals are expected to 
suffer from hypertension (Chobanian, 1983). Cross sectional and longitudinal 
studies have demonstrated a rise in blood pressure with age in industrialized 
societies. Systolic blood pressure increases in an almost linear fashion until the 
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age of 80 years whereas diastolic blood pressure increases till the age of 60 
years and later plateaus and then falls. In the National Health and Nutrition 
Examination Survey (NHANES), the prevalence and severity of hypertension 
(SBP ~ 160 mmHg and/or DBP;;: 95 mmHg) increased with age. Hypertension 
occurred in over 40% of those aged 65 to 7 4 years old. Similar prevalence 
rates were reported in the United Kingdom, based on blood pressure 
measurements on a single occasion (Burt et al, 1995). 
The rise in blood pressure with age is also influenced by the racial origin. 
Blacks tend to have greater increase than whites and women are more prone 
compared to men. Blood pressure levels are also correlated among family 
members. A number of factors possibly contribute to this and they include the 
common genetic background and the shared environment or lifestyle habits. 
Prolonged effect of a particular life style and exposure to environmental factors 
for instance has been speculated to affect the blood pressure (Potter, 1994; 
Stamler at al, 1991). Thus hypertension appears to be a complex trait that does 
not follow the classical Mendelian rules of inheritance attributable to a single 
gene locus. The currently documented exceptions are a few rare forms of 
hypertension, such as those related to a single mutation involving a chimeric 
11-B-hydroxylase/aldosterone synthase gene. Hypertension appears to be a 
polygenic and multifactorial disorder in which the interaction of several genes 
with each other and with the environment is important. Potential candidate 
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genes suggested by recent experimental data include those that affect various 
components of the renin-angiotensin-aldosterone system, the kallikrein-kinin 
system and the sympathetic nervous system. 
Due to its complexity, direct consequences and prevalence, the prevention and 
treatment of hypertension therefore represent a major public health challenge. 
Concerted efforts are required and have been shown to bear fruits. 
Hypertension prevalence rates in the United States are on the decline, perhaps 
thanks to the efforts directed toward primary prevention. In the National Health 
and Nutrition Examination Survey (Burt et al, 1995). The prevalence of 
hypertension among US adults was 20.4%, compared to 31.8o/o in NHANES II 
(1976-80) and 36.3% in NHANES I (1960-62). From NHANES II until NHANES 
Ill, hypertension control rates also improved from 1 0°/o to 29°/o and 
cardiovascular disease mortality rates have improved dramatically. However 
hypertension control rates appear to be declining. NHANES Ill Phase 2, 
completed in the early 1990s, showed control rates slipping from 29o/o in 
NHANES Ill to 27°/o. (Burt et al, 1995). We are beginning to move in the wrong 
direction. 
Thus the following continue to be among the challenges: 
1) to prevent the rise of blood pressure with age, 
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2) to decrease the existing prevalence of hypertension, 
3) to increase hypertension awareness and detection, 
4) to improve control of hypertension, 
5) to reduce other cardiovascular risks, 
6) to increase recognition of the importance of controlled isolated systolic 
hypertension, 
7) to improve recognition of the importance of high .. normal blood pressure, 
8) to reduce ethnic, socioeconomic and regional variation in hypertension, 
9) to improve opportunities for treatment and to enhance 
community programs. 
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For the treatment of high blood pressure, many antihypertensive drugs are 
available. The choice of an appropriate antihypertensive is crucial and 
therefore needs to be considered carefully. The clinician must consider a 
number of factors especially in relation to the frequency of drug administration 
and the side effects that may arise from the medications as these may affect 
compliance (Rosenthal et al, 1996; Kesaniami et al, 1991 ). The treatment goal is 
to make optimal use of antihypertensive drug therapy while encouraging 
patients to implement lifestyle changes such as weight loss, sodium restriction, 
decreased alcohol intake, and increased exercise (Hennekens, 1998). 
Pharmacologic therapy of mild-tcrmoderate hypertension can significantly 
reduce the incidence of stroke, coronary artery disease, vascular mortality and 
total mortality. 
There are a number of therapeutic options for the treatment of hypertension 
and subgroup analysis of studies have shown the significant role of age, race 
and gender in the treatment process. Results from the Systolic Hypertension in 
the Elderly Programme ,SHEP (SHEP Cooperative Research Group, 1991 ), the 
Swedish Trial in Old Patients with Hypertension ,STOP-HPT (Dahlof et al, 1991), 
The Medical Research Council Trial of treatment of hypertension in older adults 
,MRC Trial (MRC Working Party, 1992) and the Treatment of Mild Hypertension 
study,TOMHS (TOMHS Research Group, 1993) are examples. All the studies 
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used placebo-controlled and they have evaluated systolic and/or diastolic blood 
pressure. Adive drug treatment with diuretics and beta blockers were used in 
the SHEP, STOP and MRC trials, whereas in TOMHS study, they compared the 
effectiveness of lowering stage 1 diastolic blood pressure using 5 different 
antihypertensive drugs with lifestyle modification versus placebo with lifestyle 
modification alone. Again these studies strongly supported the use of drug 
therapy for hypertensive patients including the elderly men and women. In most 
of the studies, both fatal and non-fatal stroke and coronary heart disease were 
reduced. In the STOP study for example, total mortality was reduced 47% by 
drug treatment. 
Grimm ( 1996) from the University of Minnesota proposed that the 
cardiovascular risk was reduced both in men and women, regardless of the 
drugs used. This was based on a variety of critical cardiovascular endpoint 
measurements evaluated over a four years period in TOMHS study. These 
studies confirmed that the risk of cardiovascular event decreased as mean 
blood pressure decreased. In relation to age, both younger (s 60 years) and 
older (~ eo years) patients responded to antihypertensive treatment (TOMHS, 
1993). Some studies including SHEP also showed that systolic pressure might 
be a better predictor of stroke and other cardiovascular events than the diastolic 
blood pressure in the elderly (SHEP Cooperative Research Group, 1991). 
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Therefore, lowering the systolic blood pressure is clearly important to reduce 
the risk of these events in the elderly. 
Similar results were seen in MRC trial where 4000 men and women aged 65 to 
7 4 years were enrolled. They were treated with diuretics, beta blockers or 
placebo. Patients treated with diuretics experienced a 31 o/o reduction in strokes, 
44% in coronary events and 35% in cardiovascular events. In this study, more 
than 49% of the patients enrolled had isolated systolic blood pressure (SBP 
~160 mmHg) and they benefited from the treatment of hypertension (MRC 
Working Party, 1992). Other trials such as the Systolic Hypertension-Europe 
(Sys-Eur) and Shanghai Trial of Nifedipine in the elderly (STONE) trials also 
showed benefits of treat~nt in the elderly, either of isolated systolic or both 
systolic and diastolic hypertension (Staessen et al, 1997; Gong et al, 1996). 
Overall, there is enough evidence to show that treatment of hypertension can 
reduce cardiovascular morbidity and mortality. 
Experts have conflicting views on the choice of initial pharmacological therapy 
for hypertension however (American Heart and Lung Association Committee, 
1993;Guidelines Sub-Committee, 1993; Carruthers et al, 1993; Jackson et al, 
1993; Hypertension Guidelines Committee, 1991 ). However, approximately half 
the published guidelines consider that diuretics and beta-blockers are the only 
drugs that have been shown to reduce cardiovascular morbidity and mortality in 
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long-term outcome trials and recommend that they should be preferred for 
initial drug therapy. 
A physician guideline for the prevention and treatment of high blood pressure 
was recently released by the National Heart, Lung and Blood Institute (NHLBI). 
This is known as The Sixth Report of the Joint National Committee on 
Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 
VI). JNC VI recommends that diuretics and beta blockers be the first line 
treatment in patients with uncomplicated hypertension (American Heart and 
lung Association Committee, 1997). 
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1.1 Beta blockers as an antihypertensive agents. 
Many beta blockers are now available and in general they are equally effective. 
There are, however, differences between them which may affect choice in 
treating individual patients. Beta blockers can be found either with or without 
intrinsic sympathomimetic activity (ISA). ISA represents the capacity of beta 
blockers to stimulate as well as to block adrenergic receptors. They tend to 
cause less bradycardia than the other beta blockers and may also cause less 
coldness of the extremities. Each of the above categories can be further 
divided into selective and non-selective beta blockers. Examples of the 
selective beta blocker which do not have ISA include metoprolol, atenolol, 
bisoprolol and betaxolol. The first two drugs are widely used for various 
indications including hypertension and ischeamic heart disease. 
Some beta blockers are lipid soluble and some are water soluble. Atenolol, 
celiprolol, nadolol and sotalol are the most water soluble; they are less likely to 
enter the brain and may therefore cause less sleep disturbances and 
nightmares. In contrast, metoprolol which is lipid soluble, can freely cross the 
blood brain barrier. 
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Metoprolol is a selective B 1-adrenoceptor antagonist with a predominant effect 
on the cardiac 81 receptors. Like other beta blockers, it has multiple actions to 
lower the blood pressure. It: 
a) blocks the cardiac 81 receptors and therefore it slows the heart rate 
at rest and after exercise via negative chronotropic affect. It also 
reduces the force of contraction, resulting in lowering of the cardiac 
output through its negative inotropic effect. 
b) reduces the central sympathetic discharge to decrease the 
peripheral vascular resistance; and 
c) suppresses the renal secretion of renin (mediated by B 1) causing 
inhibition of the renin-angiotensin-aldosterone system. 
In the treatment of ischaemic heart disease, beta blockers reduce the impact of 
beta-adrenergic stimulation of the heart. It therefore reduces the cardiac work 
toad and myocardial oxygen consumption. It also has anti arrhythmic effect 
and recently it has been proposed as one of the drugs of choice in the 
treatment of heart failure. The exact mechanism in heart failure is unknown but 
several possibilities have been proposed including upregulation of B receptors 
and increase receptor density, providing anti arrhythmic activity or protection 
against cardiotoxic effects of catecholamines. 
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Metoprolol is a competitive B 1-selective adrenergic antagonist, similar to 
atenolol. In contrast to pindolol, metoprolol does not have intrinsic 
sympathomimetic activity and does not exhibit membrane stabilizing activities 
as do both pindolol and propanolol. Metoprolol is more lipid soluble than 
atenolol, but less than propanolol and betaxolol. This affects its route of 
elimination and, theoretically, its potential for CNS side effects. Metoprolol also 
has the shortest half-life of the cardioselective B blockers. 
Metoprolol competes with adrenergic neurotransmitters (eg. Catecholamines) 
for binding at sympathetic receptor sites. At lower doses metoprolol selectivety 
blocks B-adrenergic receptors in the heart and vascular smooth muscle. As a 
result, it reduces both the resting and exercise heart rate and cardiac output 
together with the reduction in systolic and diastolic blood pressure. Selectivity 
for the B 1-receptor is lost at higher doses (~ 400 mg/day) and it can also 
competitively block a-adrenergic receptors in the bronchial and vascular 
smooth muscles, causing bronchospasm. 
Other than the use for the treatment of hypertension and ischeamic heart 
disease, metoprolol also has been used in the management of hereditary and 
familial essential tremor. 
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Metoprolol is rapidly and almost completely absorbed from the gut. but only 
50% of an oral dose reaches the systemic circulation as unchanged drug 
because of first-pass metabolism in the liver. Hypotensive effects begin within 
eo minutes of an oral dose of the immediate·release product. The maximal 
therapeutic effect occurs within the first week of treatment. 
Metoprolol is widely distributed throughout the body, crosses the blood brain 
barrier and the placenta; and is concentrated in the breast milk. Even though it 
is not extensively bound to plasma proteins, the hypotensive effects can last up 
to one month after discontinuation of the drug, possibly because of extensive 
tissue binding. 
Metabolism of metoprolol occurs primarily in the liver and both both its alpha-
hydroxylation and O-demethylation are mediated by debrisoquine-hydroxylase (Huang 
et al, 1999). Oebrisoquine hydroxylase (CYP206) is highly polymorphic with large 
interethnic variations. Up to 1 Oo/o of Whites are enzyme-deficient and are termed poor 
metabolisers (PM). Most are homozygous for CYP206*4, a mutant caused by an 
aberrant 3' splice recognition site. Another allele causing the PM phenotype in Whites 
is CYP2D6*3, a mutant caused by a single base deletion in exon 5. These alleles 
were relatively common in Whites but were absent or rare in Asians (Bertilsson et al, 
1992; Lee et al, 1994; Johansson et al, 1994; Dahl et al, 1995). Compared to Whites, 
MR among Chinese extensive metabolizers (EMs) is shifted toward higher values. An 
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enrichment occurred in the log MR values between 0.2 to 1.0, indicating lower 
average activity (Lee and Jayaseelan, 1995). The mechanism is mutations that 
caused reduced enzyme activity. As an example, CYP206*10 was common in Asia 
but not among Whites (Johansson et al, 1994; Dahl et al, 1995; Armstrong et al, 1994). 
This allele has a mutation in C188 ->Tin exon 1 that caused reduced enzyme activity. 
The C 188 -> T polymorphism resulted in higher metoprolol plasma concentrations and 
lower urinary metoprolol metabolite .levels in Chinese subjects and this finding 
suggests that a lower dose of metoprolol may be used in these subjects (Huang et al, 
1999). 
Metoprolol is generally well tolerated. Its adverse effects are generally mild and 
temporary usually occurring at the onset of therapy and diminishing over time. 
As most of its adverse reactions are extensions of its therapeutic affect and 
could thus be due to excessive plasma concentrations, its use among our local 
population may therefore be associated with a different spectrum of adverse 
effects due to the difference in the genetic polymorphism of CYP206 in the 
local population. Thus although its use is well studied in Western populations, 
direct extrapolation can be dangerous. Among the recognized side effects of 
metoprolol include:-
1) Sinus bradycardia. 
2) Hypotension. 
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3) Congestive cardiac failure especially in patients with preexisting left 
ventricular dysfunction. 
4) CNS side effects including dizziness, fatigue, mental depression and in 
some cases vivid dreams. 
5) GIT side effects including diarrhea, nausea and vomiting. 
6) Bronchospasm and dyspnoea that are more likely to occur if the dose 
is more than 400 mg/day as the beta ~lectivity of the drug is lost. 
7} Hypoglycaemia and hyperglycaemia. 
8) Hematological adverse reactions such as agranulocytosis. 
9) Hypertriglyceridemia and decrease plasma HDLs duringtherapy. 
1 0) Myalgia and musculoskeletal pain. 
11) Elevated hepatic enzymes. 
12) Sexual dysfunction, impotence and decrease libido. 
13) Dermatological problems : pruritus, skin hyperpigmentation reversible 
alopecia, xerosis and exfoliative dermatitis. 
Although metoprolol is generally well tolerated, it should be used cautiously in 
certain condition especially in the patient who has an underlying cardiac 
disease and in thyrotoxic patients as abrupt discontinuation of the drug can 
precipitate myocardial ischaemia, infarction, ventricular arrythmias or severe 
hypertension and thyroid storm respectively. This drug is also contraindicated 
in severe bradycardia or advanced AV block, in the patients with cardiogenic 
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shock or systolic congestive heart failure, particularly in those with severe 
compromised left ventricular dysfunction. It should also not be used as a 
monotherapy in patients with pheochromocytoma. Metoprotol should also be 
used cautiously in diabetic and bronchial asthmatic patients. 
In summary, hypertension is common but it can cause significant morbidity and 
mortality if not properly recognized and treated. On the other hand the 
treatment of hypertension is not without risk as it may cause unnecessary side 
effect which can affect the patient's quality of life. The use of drugs like 
metoprolol which undergoes metabolism via an enzyme that is polymorphic 
may pose special problems. A balance must therefore be seeked to ensure that 
the pateints are treated adequately and remained on the treatment for the rest 
of their natural lives. Starting antihypertensive therapy alone is not sufficient. 
Patients have to remain on the drugs until the ends of their natural lives and it 
is therefore disheartening that nearly 86o/o of new antihypertensive drug therapy 
patients interrupted or discontinued purchasing any form of antihypertensive 
medications during the first year of a study (McCombs JS et al, 1994), thus 
negating its potential benefits. Inability to adequately metabolise metoprolol as 
it would occur with patients with mutated CYP206 gene may cause an 
increased incidence of adverse effects that may eventually translate into non 
compliance. 
16 
1.2 Health-related Quality Of Life (HRQOL). 
The term quality of life has been widely used in a number of disciplines to 
express the idea of personal wellbeing in a framework which goes beyond the 
simple economistics equation of wellbeing with income (Jacobs, 1997). 
Christopher J. Bulpitt defined it as the degree of subjective well being 
attributable to or associated with lack of symptoms, psychological state and 
activities pursued (Bulpitt, 1997). Others defined it as multifactorial 
psychological construd consisting of the minimum of physical, psychological, 
social and behavioral aspects of well-being and function as perceived by the 
patient (Aaronson and Bullinger et al, 1991). 
Health related quality of life is the beliefs and behaviors of daily life which are 
governed by the degree of good or ill health that an individual, group or 
population experiences (Irvine, 1996). Health status and functional status are 
other terms often used to denote HRQOL. In fact the above three objects are 
often used interchangeably to refer to the health domain which ranges from 
negatively valued aspects of life including death to the other end of the 
spectrum of positively valued aspects eg. role function of happiness (Guyatt et 
al, 1993). 
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Drossman et al. described a model of HRQOL which included disease related 
features (disease symptoms, complications of the disease or side effects of 
treatment) and non disease features (such as cognitive function, personality, 
social support network, cultural practices and religion) (Garret and Crossman, 
1990). Typical domains of HRQOL assessments include well being, pain and 
discomfort, body image and sexuality, mobility and ability to perform activities, 
ability to work or attend school and engagement in personal relationships. 
Traditionally, HRQOL is described from the patient's point of view (group or 
population), because physicians and family under-estimate or introduce bias in 
the assessment of disease impact (Guyatt et al, 1993). 
The potential applications of HRQOL assessment have been summarized by 
Fitzpatrick (Fitzpatrick et al, 1992). These include identification of the problems 
and needs of individuals or groups of patients, assessment of standard of 
health care, enhancement of knowledge concerning the disease clinical course 
and measurement of treatment efficacy in clinical trials. Furthermore HRQOL 
assessment is critical for economic (cost effectiveness and cost utility) 
analyses. 
Three general measures of quality of life have been widely employed: 
1. Sickness Impact Profile (SIP). 
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2. Nottingham Health Profile (NHP). 
3. Quality of Well-Being Scale (QWB). 
Each of the category carries advantage and disadvantages. For example, the 
QWB scale was found to be less useful than the SIP or NHP for the following 
reasons: 
-it always need and interviewer. 
-it is lengthy and difficult to administer. 
-the overall score is dominated by the symptom scores and 
-a single symptom is rated as the most distressing. 
Comparing the SIP and NHP, the SIP is likely to be more sensitive to changes 
than NHP. Furthermore it requires less patients to demonstrate a given 
difference between the two groups studied. Many researchers now are 
replacing the above three general or generic measures with the short-form 36-
item (SF-36) instrument. However prove is still required that 36 questions can 
replace the 136 questions of the SIP without loss of sensitivity to change or the 
emergence of floor and ceiling effects (Bulpitt, 1997). 
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Table I. General measures of the quality of life. The summaries of the 
characteristics of the instruments. 
·- . -Covers important area? 
In dept' enquires? 
Number of item 
Can be self-administered? 
Average time for completion 
{min) 
Valid and repeatable 
Floor and ceiling effect 
SIP NHP QWB 
yes yes yes 
yes no yes 
136 45 varies 
yes yes no 
35 10 45 
yes yes yes 
minor major minor 
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There are three main types of instrument which have been used to assess 
HRQOL and they include: 
1. Global index. 
- HRQOL is usually of secondary importance to the study or questions, 
- Summarizes HRQOL at a glance, 
- Provides little information as to the cause(s) of impairment. 
2. Generic instrument. 
- is more comprehensive than a global assessment, 
- permits comparisons among populations interventions, 
• may be insensitive to detect subtle but important specific changes in 
status. 
3. Disease---specific instrument. 
_ is best suited to detect important changes within populations (with 
time or treatment), 
_ may not be available for a particular disease, 
_ may be too detailed to discriminate among similar disease. 
The interpretation of quality of life data is therefore important for therapeutic 
decision making and policy planning. The measurement properties of the 
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quality of live indices and scales used in therapeutic trials affect their ability to 
detect meaningful treatment differences. 
Whichever the instruments used, whether disease-specific or generic 
instruments, should be adequately validated prior to their application in clinical 
research or practice. Validation of new HRQOL instrument requires a 
comparison with a currently accepted reference measure (criterion validation) 
or a hypothetical prediction of its performance (construct validation). Both a 
Health Status Index (HSI) and a health profile should be obtained where a HSI 
is a summary score that encompasses all the quality of life data, whereas a 
health profiles are instruments that attempt to measure all important aspects of 
HRQOL for example, the Sickness Impact Profile. Their use will assist in 
avoiding the missing of important observations or focusing on inconsequential 
problems. 
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CHAPTER TWO 
OBJECTIVES 
2. OBJECTIVES. 
1. To determine the incidence of adverse events in patients given metoprolol. 
2. To determine factors that govern occurrences of adverse drug reaction. ie. 
demography data. 
3. To determine whether patients who develop side effect to metoprolol suffer 
reduced quality of life. 
4. To compare objectives number 1, 2 and 3 with patients treated with enalapril. 
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CHAPTER THREE 
METHOD 
3. METHODOLOGY. 
The study was part of a larger study to investigate the relevance of CYP206 
polymorphism in patients with cardiovascular disease and received appropriate 
approvals of the Ethical Committee at USM. 
3.1 Patient selection. 
Consecutive patients attending the specialist medical clinic at HUSM for the treatment 
of hypertension were recruited if they satisfied the following inclusion and exclusion 
criteria: 
3.1.1 Inclusion criteria: 
1. Willingness to sign a written-informed consent. 
2. Diagnosed with hypertension and treated with metoprolol and/or 
enalapril. 
3. Ability to understand the protocols of the study. 
4. Willingness to participate in the study and to follow all prescribed 
instructions. 
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